Do intravitreal anti-vascular endothelial growth factor agents lead to renal adverse events? A pharmacovigilance real-world study

Do intravitreal anti-vascular endothelial growth factor agents lead to renal adverse events? A pharmacovigilance real-world study

PurposeIntravitreal vascular endothelial growth factor (VEGF) blockade is essential in many macular edema diseases treatment. However, intravitreal VEGF treatment has been reported to lead to deteriorated proteinuria and renal function. This study aimed to explore the relationship between renal adve...

Full description

Bibliographic Details
Main Authors: Lin Jiang, Liying Peng, Yangzhong Zhou, Gang Chen, Bin Zhao, Mingxi Li, Xuemei Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Medicine
Subjects:
acute kidney injury
vascular endothelial growth factor
adverse event reporting system
pharmacovigilance
ophthalmic medicine
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1100397/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1100397/full

Similar Items